The Icelandic Medicine Pricing and Reimbursement Committee has approved the subsidy of Emtricitabine/Tenofovir disoproxil Krka for HIV prevention, mbl.is reports. The drug combination, often known as the PrEP treatment, helps prevent HIV-negative people from contracting the virus. Though the treatment has long been available in Iceland, it was not subsidised by the government.
“The Chief Medical Officer believes that the Medicine Pricing Committee’s decision is a milestone in the fight against HIV and other sexually transmitted diseases as the Chief Medical Officer and a task force of the Minister of Health on prevention of sexually transmitted diseases have previously pointed out the importance of this step,” a statement on the Directorate of Health website reads.
The approval is valid for a one-year period and will be re-evaluated based on cost and number of individuals who seek the treatment.
Those who are interested in taking advantage of the above treatment are advised to make an appointment at the National University Hospital by telephone at 543-6040.